Semaglutide MASH Trial: 62% Complete Resolution in Phase 3 Study | FormBlends

Clinical evidence from the ESSENCE trial shows semaglutide achieved 62% complete resolution of MASH (metabolic dysfunction-associated steatohepatitis) versus 34% with placebo over three years. The study also demonstrated significant improvements in liver fibrosis, supporting weight loss as a primary treatment mechanism for this severe form of fatty liver disease.

Full FormBlends page: https://formblends.com/videos/glp1/ozempic-liver

What this video actually says (full transcript):
Have you heard about ozempic liver? Results from a phase 3 clinical trial called the Essence Trial were published in the New England Journal of Medicine. It took people with a form of fatty liver disease called mash, divided them into two groups. One group got somaglotide and one group got placebo and they were monitored for three years. At the end of the three years, 62% of people in the somaglotide group had complete resolution of their mash compared to 34% of the placebo group. Also 36% of people in the somaglotide group had improvement in their fibrosis, which is scarring of the liver compared to 22% of people in the placebo group. Mash stands for metabolic dysfunction associated steatohepatitis. This was previously known as Nash non-alcoholic steatohepatitis and a few years ago it was renamed to more closely reflect the origins of the disease. Fatty liver disease is pretty common. About 30% of Americans have some form of fatty liver disease where there's extra fat deposited in and around the liver. Mash is a more severe form of fatty liver disease. About 5% of people have this and it's associated not just with fatty deposits but also injury and inflammation to the liver cells. Fatty liver disease increases in parallel to other metabolic diseases including diabetes and obesity and it's projected by 2030 that mash will be the number one cause of liver failure requiring liver transplant. The primary treatment of mash and fatty liver is weight loss and so it makes sense that somaglotide could be helpful with that.

Topics covered:
semaglutide MASH trial, ESSENCE trial results, fatty liver disease treatment, metabolic dysfunction steatohepatitis, liver fibrosis improvement, semaglutide liver benefits, NASH vs MASH, GLP-1 fatty liver, phase 3 clinical trial, liver transplant prevention, metabolic liver disease, ozempic liver effects, steatohepatitis resolution, liver inflammation treatment, weight loss liver health

Evidence and source references:
- Loomba et al., 2025
- Rinella et al., 2023

Related third-party FormBlends context:
- A Nation of Moms - Wegovy vs Zepbound: https://anationofmoms.com/2026/04/wegovy-vs-zepbound.html
- Neurodivergent News Medium - The Cycle of Weight Loss: https://gystassist.medium.com/the-cycle-of-weight-loss-gain-my-journey-fa035c5539fe

About this video: this is third-party social media content, shared by FormBlends for informational and commentary purposes and to add evidence-based context. The creator is not affiliated with FormBlends and is not discussing, promoting, or endorsing FormBlends or any FormBlends product. FormBlends did not produce this footage, does not own it, and does not endorse the creator or any product, dose, brand, or seller they mention. All views expressed are the creator's own opinions.

Not medical advice. This content is for general education only. GLP-1 medications, peptides, and hormone therapies carry real risks and should only be used under the care of a licensed healthcare provider. Some products discussed by online creators are compounded or are not FDA approved. Always talk to a qualified clinician before starting, stopping, or changing any treatment.

#FormBlends #GLP1 #Peptides #TRT #Health

Видео Semaglutide MASH Trial: 62% Complete Resolution in Phase 3 Study | FormBlends канала Form Blends